This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will be identified at the oncology clinic and will be included in the study if all eligible criteria are met. The study will involve retrospective and prospective evaluations. Safety will be assessed through reporting of serious adverse events (SAEs) related to study procedures.
The aim of this study is to identify and evaluate cardiotoxicity in patients with diagnosis of breast cancer, lymphoma or leukemia scheduled to receive anthracycline-based chemotherapy (Cohort A: prospective evaluation); and patients undergoing or having received within the last 5 years anthracycline-based chemotherapy (Cohort B: retrospective and prospective evaluations). Part A and B will be conducted in parallel. This study also has the objectif of identifying biomarkers of cardiotoxicity including inflammatory response proteins and clonal hematopoiesis.
Study Type
OBSERVATIONAL
Enrollment
169
Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
Collection of retrospective data
Centre Hospitalier de l'université de Montréal (CHUM)
Montreal, Quebec, Canada
CIUSSS Ouest de l'ile de Montreal - St-Mary's Hospital
Montreal, Quebec, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
CIUSSS du Centre-Ouest de l'Île de Montréal - Jewish General Hospital
Montreal, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
CISSSS de Lanaudière_Hôpital Pierre LeGardeur (referring site)
Terrebonne, Quebec (QC), Canada
Myocardial extracellular volume (ECV)
Cohort A
Time frame: Change from baseline to 3, 6, 12,and 24 months
Myocardial extracellular volume (ECV)
Cohort B
Time frame: Change from baseline to prior study entry, 12 and 24 months post study entry.
Left ventricular (LV) systolic function (global and regional)
Cohort A
Time frame: Change from baseline to 3, 6, 12,and 24 months.
Biomarker of myocardial injury (high-sensitivity troponin (hs-cTn))
Cohort A
Time frame: Change from baseline to 3, 6, 12,and 24 months.
Biomarker of elevated LV fitting pressure (N-Terminal-pro-hormone B-type Natriuretic Peptide (NT-proBNP))
Cohort A
Time frame: Change from baseline to 3, 6, 12,and 24 months.
Biomarker of inflammation (high-sensitivity C-reactive protein (hs-CRP))
Cohort A
Time frame: Change from baseline to 3, 6, 12,and 24 months.
Clonal hematopoiesis associated gene mutations.
Cohort A
Time frame: Change from baseline to 24 months..
Telomere length measurement
Cohort A
Time frame: Change from baseline to 24 months..
Left ventricular (LV) systolic function (global and regional)
Cohort B
Time frame: Change from study entry to 12 and 24 months.
Biomarker of myocardial injury (high-sensitivity troponin (hs-cTn))
Cohort B
Time frame: Change from study entry to 12 and 24 months.
Biomarker of elevated LV fitting pressure (N-Terminal-pro-hormone B-type Natriuretic Peptide (NT-proBNP))
Cohort B
Time frame: Change from study entry to 12 and 24 months.
Biomarker of inflammation (high-sensitivity C-reactive protein (hs-CRP))
Cohort B
Time frame: Change from study entry to 12 and 24 months.
Clonal hematopoiesis associated gene mutations.
Cohort B
Time frame: Change from baseline to 24 months..
Telomere length measurement
Cohort B
Time frame: Change from baseline to 24 months..
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.